Skip to main content

Advertisement

Log in

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

To assess the role of various epidermal growth factor receptor (EGFR) mutations and HER2/3 protein expression as predictive markers of responsiveness to gefitinib therapy in Chinese patients with advanced non-small cell lung cancer (NSCLC).

Methods

A total of 106 Chinese NSCLC patients who had failed at least one chemotherapy regimen received gefitinib 250 mg once daily. All the 106 tumors from these patients were screened for mutations in the EGFR exons 18–24, and 84 tumors were studied by immunohistochemistry for HER2/3 expression and correlated with clinical treatment outcome.

Results

Patients with EGFR mutations had a significantly higher overall response rate (ORR), longer time to progression (TTP) and overall survival (OS) compared with those with wild-type receptor. No difference in ORR was observed between patients with exon 19 deletion and patients with other EGFR mutations. ORR in HER2-positive patients was significantly higher than in the HER2-negative group, irrespective of EGFR mutational status, and a trend for better ORR was observed for HER3-positive patients. HER2 and HER3 expression levels were not associated with any difference in terms of TTP and OS. Nevertheless, when considering the subgroups of non-responders to gefitinib, median TTP in patients with mutated EGFR was significantly longer than in those with no mutations (8.0 vs. 3.0 months, P = 0.0065). EGFR-mutated patients had no significant difference in ORR, TTP and OS according to HER2 and/or HER3 expression.

Conclusions

EGFR mutations are effective predictors for gefitinib efficacy in Chinese patients with advanced NSCLC. HER2 and HER3 expression does not provide any additional information for selecting patients most likely to benefit from gefitinib treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274–1283

    PubMed  CAS  Google Scholar 

  • Arteaga C (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29:3–9

    PubMed  CAS  Google Scholar 

  • Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95(8):998–1004

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F (2008) EGFR FISH versus mutation: different tests. Different end-points. Lung Cancer 60:160–165. doi:10.1016/j.lungcan.2008.02.008

    Article  PubMed  Google Scholar 

  • Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandrio C, de Rosa M, Villa E, Crino L (2003) Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658–2663. doi:10.1200/JCO.2003.01.039

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR (2005a) Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23:5007–5018. doi:10.1200/JCO.2005.09.111

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al (2005b) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97:643–655

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E et al (2005c) HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 93:1334–1340. doi:10.1038/sj.bjc.6602865

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R et al (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25(16):2248–2255. doi:10.1200/JCO.2006.09.4300

    Article  PubMed  CAS  Google Scholar 

  • Chen X, Yeung TK, Wang Z (2000) Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 277:757–763. doi:10.1006/bbrc.2000.3731

    Article  PubMed  CAS  Google Scholar 

  • DAKO HercepTest package insert (1998) Carpinteria. DAKO Corp, California

  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900–5909. doi:10.1200/JCO.2005.02.857

    Article  PubMed  CAS  Google Scholar 

  • Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102:3788–3793. doi:10.1073/pnas.0409773102

    Article  PubMed  CAS  Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043

    Article  PubMed  CAS  Google Scholar 

  • Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE et al (2005) High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65:11478–11485. doi:10.1158/0008-5472.CAN-05-1977

    Article  PubMed  CAS  Google Scholar 

  • Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313. doi:10.1371/journal.pmed.0020313

    Article  PubMed  CAS  Google Scholar 

  • Haneda H, Sasaki H, Lindeman N, Kawano O, Endo K, Suzuki E, Shimizu S, Yukiue H, Kobayashi Y, Yano M, Fujii Y (2006) A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 36(2):69–75

    Article  PubMed  Google Scholar 

  • Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T et al (2005) HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65:4253–4260. doi:10.1158/0008-5472.CAN-04-2748

    Article  PubMed  CAS  Google Scholar 

  • Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034–5042. doi:10.1200/JCO.2006.06.3958

    Article  PubMed  CAS  Google Scholar 

  • Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY et al (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small-cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195–8203. doi:10.1158/1078-0432.CCR-04-1245

    Article  PubMed  CAS  Google Scholar 

  • Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N et al (2006) Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 20:3340–3346. doi:10.1200/JCO.2005.05.4692

    Article  CAS  Google Scholar 

  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA et al (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12:3908–3914. doi:10.1158/1078-0432.CCR-06-0462

    Article  PubMed  CAS  Google Scholar 

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  • Kaplan EL, Meier P (1985) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481. doi:10.2307/2281868

    Article  Google Scholar 

  • Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792. doi:10.1056/NEJMoa044238

    Article  PubMed  CAS  Google Scholar 

  • Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G et al (2001) Coexpression patterns of EGFR, HER2, HER3 and HER4 in nonmelanoma skin. Eur J Cancer 37:251–259. doi:10.1016/S0959-8049(00)00364-6

    Article  PubMed  CAS  Google Scholar 

  • Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E et al (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385–3397. doi:10.1093/emboj/17.12.3385

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139. doi:10.1056/NEJMoa040938

    Article  PubMed  CAS  Google Scholar 

  • Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550–6565. doi:10.1038/sj.onc.1204082

    Article  PubMed  CAS  Google Scholar 

  • Moasser MM, Basso A, Averbuch SD, Rosen N (2001) The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184–7188

    PubMed  CAS  Google Scholar 

  • Naidu R, Yadav M, Nair S, Kutty MK (1998) Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78:1385–1390

    PubMed  CAS  Google Scholar 

  • Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500. doi:10.1126/science.1099314

    Article  PubMed  CAS  Google Scholar 

  • Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17. doi:10.1371/journal.pmed.0020017

    Article  PubMed  CAS  Google Scholar 

  • Paz-Ares L, Sanchez JM, Garc′ıa-Velasco A, Massuti B, L′opez-Vivanco G, Provencio M et al (2006) A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 24:18s–7020a

    Google Scholar 

  • Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES et al (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12(3 Pt 1):839–844. doi:10.1158/1078-0432.CCR-05-1846

    Article  PubMed  CAS  Google Scholar 

  • Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232. doi:10.1016/1040-8428(94)00144-I

    Article  PubMed  CAS  Google Scholar 

  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Eastern Cooperative Oncology Group et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98. doi:10.1056/NEJMoa011954

    Article  PubMed  CAS  Google Scholar 

  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA et al (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26(15):2442–2449

    Article  PubMed  CAS  Google Scholar 

  • Shepherd FA (2008) Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol 26(15):2426–2427

    Article  PubMed  Google Scholar 

  • Shepherd FA, Tsao MS (2006) Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24(7):1219–1220

    Article  PubMed  Google Scholar 

  • Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, National Cancer Institute of Canada Clinical Trials Group et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132. doi:10.1056/NEJMoa050753

    Article  PubMed  CAS  Google Scholar 

  • Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K et al (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56(3):383–389. doi:10.1016/j.lungcan.2007.01.025

    Article  PubMed  Google Scholar 

  • Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, Hagiwara K, Kobayashi K (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95(11):1483–1489

    Article  PubMed  CAS  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537. doi:10.1016/S0140-6736(05)67625-8

    Article  PubMed  CAS  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205

    Article  PubMed  CAS  Google Scholar 

  • Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144. doi:10.1056/NEJMoa050736

    Article  PubMed  CAS  Google Scholar 

  • Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T (2007) Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2(5):430–439

    Article  PubMed  Google Scholar 

  • Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K et al (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2(1):22–28. doi:10.1097/01243894-200701000-00006

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jian Ming Xu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, J.M., Han, Y., Duan, H.Q. et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 135, 771–782 (2009). https://doi.org/10.1007/s00432-008-0512-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0512-1

Keywords

Navigation